Probiotec Limited, in the matter of Probiotec Limited

Link copied
Case Copied 34 min read

FEDERAL COURT OF AUSTRALIA

Probiotec Limited, in the matter of Probiotec Limited [2024] FCA 298

File number(s): VID 182 of 2024
Judgment of: BUTTON J
Date of judgment: 26 March 2024
Date of publication of reasons: 28 March 2024
Catchwords: CORPORATIONS – scheme of arrangement – first court hearing – application under s 411(1) of the Corporations Act 2001 (Cth) to convene a meeting to consider a proposed scheme of arrangement by acquisition of shares – orders made
Legislation:

Corporations Act 2001 (Cth) ss 110C, 110D, 411, 412, 1319, Sch 2 (Insolvency Practice Schedule (Corporations)) Div 75

Corporations Regulations 2001 (Cth) reg 5.1.01, Pt 3 of Sch 8

Federal Court (Corporations)Rules 2000 (Cth) rr 1.3, 2.4, 2.15, 3.4

Insolvency Practice Rules (Corporations) 2016 (Cth) Div 75

Cases cited:

Re Clemenger Group Ltd [2023] FCA 815

Re DWS Limited (2020) 148 ACSR 616; [2020] FCA 1590

Re Essential Metals Limited (No 2) [2023] FCA 1306

Re Healthscope Ltd (2019) 139 ACSR 608; [2019] FCA 542

Re Security Matters Limited [2023] FCA 19

Re Skilled Group Ltd (No 1) (2015) 113 ACSR 525; [2015] VSC 789

Sovereign Life Assurance Co v Dodd [1892] 2 QB 573

Division: General Division
Registry: Victoria
National Practice Area: Commercial and Corporations
Sub-area: Corporations and Corporate Insolvency
Number of paragraphs: 71
Date of hearing: 26 March 2024
Counsel for the Plaintiff: M Izzo SC with B Holmes
Solicitor for the Plaintiff: Arnold Bloch Leibler
Counsel for the Bidder: J Rudd
Solicitor for the Bidder: Ashurst

ORDERS

VID 182 of 2024

IN THE MATTER OF PROBIOTEC LIMITED

PROBIOTEC LIMITED

Plaintiff

ORDER MADE BY:

BUTTON J

DATE OF ORDER:

26 MARCH 2024

THE COURT ORDERS THAT:

1.Pursuant to r 2.13(1) of the Federal Court (Corporations) Rules 2000 (Cth) (Rules), PYFA Australia Pty Ltd has leave to be heard in the proceeding without becoming a party to it.

2.Pursuant to s 411(1) and s 1319 of the Corporations Act 2001 (Cth) (Act), the plaintiff (PBP) convene and hold a meeting of its members (Scheme Meeting):

(a)for the purpose of considering and, if thought fit, agreeing (with or without modification) to the scheme of arrangement (Scheme) proposed to be made between PBP and its shareholders, the terms of which are set out at pages 1077 to 1145 of Annexure JMW-2 to the affidavit of Jonathan Michael Wenig dated 21 March 2024 (Wenig Affidavit);

(b)to be held on Wednesday, 29 May 2024 commencing at 10:00am (AEDT) and to be conducted simultaneously in person at the offices of Arnold Bloch Leibler, Level 21/333 Collins Street, Melbourne VIC 3000, and virtually via an online platform.

3.Pursuant to s 411(1) and s 1319 of the Act, the Scheme Meeting be convened by sending on or before 30 April 2024:

(a)to each PBP shareholder who has nominated an electronic address for the purpose of receiving communications from Probiotec or who has otherwise elected to be sent company meeting documents in…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Probiotec Limited, in the matter of Probiotec Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCA 298
Decision Date

CaseChat Overview and Summary

Probiotec Limited applied to the Federal Court for orders convening a meeting of its members to consider a proposed scheme of arrangement by acquisition of shares. The court was required to decide whether the procedural requirements for convening the meeting had been satisfied and if the scheme was fair and appropriate enough to be put before the shareholders. The court examined the details of the scheme, the consideration offered, and the manner in which the meeting would be conducted. The court concluded that the procedural requirements had been met and that there was no reason to prevent the scheme from being put to a vote by the shareholders. The court ordered the convening of the meeting and specified the method of communication with shareholders, the conduct of the meeting, and other procedural matters.

The court also considered the fairness of the scheme and concluded that it was not so unfair or inappropriate as to warrant refusal at the approval hearing. The scheme offered a premium over the share price and allowed for certain dividends without affecting the consideration. The court was satisfied that the shareholders would be properly informed about the scheme and that the scheme was likely to gain approval if passed by the necessary majorities. Therefore, the court granted the orders convening the meeting and related matters, subject to certain conditions and compliance with the Federal Court (Corporations) Rules 2000 (Cth). The further hearing of the originating process was adjourned to another date and time.

Orders

Orders of the court

1. Pursuant to r 2.13(1) of the Federal Court (Corporations) Rules 2000 (Cth) (Rules), PYFA Australia Pty Ltd has leave to be heard in the proceeding without becoming a party to it.

2. Pursuant to s 411(1) and s 1319 of the Corporations Act 2001 (Cth) (Act), the plaintiff (PBP) convene and hold a meeting of its members (Scheme Meeting):

(a) for the purpose of considering and, if thought fit, agreeing (with or without modification) to the scheme of arrangement (Scheme) proposed to be made between PBP and its shareholders, the terms of which are set out at pages 1077 to 1145 of Annexure JMW-2 to the affidavit of Jonathan Michael Wenig dated 21 March 2024 (Wenig Affidavit);

(b) to be held on Wednesday, 29 May 2024 commencing at 10:00am (AEDT) and to be conducted simultaneously in person at the offices of Arnold Bloch Leibler, Level 21/333 Collins Street, Melbourne VIC 3000, and virtually via an online platform.

3. Pursuant to s 411(1) and s 1319 of the Act, the Scheme Meeting be convened by sending on or before 30 April 2024:

(a) to each PBP shareholder who has nominated an electronic address for the purpose of receiving communications from Probiotec or who has otherwise elected to be sent company meeting documents in electronic form (Email Shareholders), an email substantially in the form of the draft email which appears at tab 13 of Annexure JMW-1 (at page 841 of the Court Book) to the Wenig Affidavit containing hyperlinks to:

(i) a website (Scheme Booklet Website) at which the Email Shareholder can view and download an electronic copy of a document substantially in the form of the document which is Annexure BFO-5 to the affidavit of Benjamin James Friis-O’Toole dated 25 March 2024 (including its annexures) and incorporating the amendments to that document identified in Annexures JSL-1 and JSL-2 to the affidavit of Jeremy Simon Lanzer dated 26 March 2024 (Scheme Booklet);

(ii) a website (Proxy Website) through which the Email Shareholder can electronically lodge proxy instructions in relation to their shareholding or shareholdings and lodge questions prior to the Scheme Meeting; and

(iii) an online meeting platform (Online Meeting Platform) which enables the Email Shareholder to view, listen to and participate in the Scheme Meeting online;

(b) to each PBP shareholder who is not an Email Shareholder and who has nominated a physical address for the purpose of receiving communications from PBP or who has otherwise elected to be sent company meeting documents in physical form (Hard Copy Shareholders) and whose registered address is in Australia, the following documents in hard copy by ordinary post:

(i) the Scheme Booklet;

(ii) a personalised proxy form substantially in the form of the draft proxy form which appears at tab 15 of Annexure JMW-1 (at pages 844 – 845 of the Court Book) to the Wenig Affidavit (Proxy Form);

(iii) a reply-paid envelope for the return of the Proxy Form; and

(c) to each Hard Copy Shareholder whose registered address is outside Australia, a hard copy letter substantially in the form of the draft letter which appears at tab 14 of Annexure JMW-1 (at pages 842 – 843 of the Court Book) to the Wenig Affidavit (Shareholder Letter) by prepaid airmail or air courier which:

(i) explains how a hard copy of the Scheme Booklet can be requested;

(ii) includes URLs from which the Hard Copy Shareholder can access the Scheme Booklet Website, the Proxy Website and the Online Meeting Platform; and

(iii) encloses a hard copy Proxy Form for the Scheme Meeting; and

(d) to each PBP shareholder who is not an Email Shareholder or a Hard Copy Shareholder (Non Electing Shareholders), the Shareholder Letter (enclosing a hard copy Proxy Form) by ordinary post (in the case of Non Electing Shareholders with a registered address in Australia) or by airmail or air courier (for Non Electing Shareholders with a registered address outside Australia).

4. Voting on the resolution to agree to the Scheme is to be conducted by way of a poll.

5. A proxy in respect of the Scheme Meeting will be valid and effective if, and only if, it is completed and delivered in accordance with its terms or a proxy is lodged online in accordance with the instructions on the Proxy Website and received by PBP by 10:00am (AEDT) on 27 May 2024.

6. Mr Jonathan Wenig or, failing him, Mr Simon Gray be Chairperson of the Scheme Meeting.

7. PBP must cause an announcement to be published on the ASX Announcements platform by no later than 28 May 2024 setting out the details for the second Court hearing and the process for any person wishing to appear at that hearing to oppose the approval of the Scheme, together with an address for service of PBP.

8. Pursuant to r 1.3 of the Rules, compliance with the following provisions of the Rules be dispensed with:

(a) r 2.4(1) to the extent that the rule requires the affidavit filed with the Originating Process to state all the facts in support of the Originating Process;

(b) r 2.15; and

(c) r 3.4 and Form 6.

9. The further hearing of the Originating Process is adjourned to the Honourable Justice Button at 10:15am on 5 June 2024.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Probiotec applied to the court for orders pursuant to s 411(1) of the Corporations Act 2001 (Cth) (the Act) convening a meeting of its members to consider, and if thought fit, agree to the Scheme, as well as certain orders as to the manner in which the meeting is to be conducted. I made those orders on 26 March 2024. These are my reasons for making orders convening the meeting and related matters.The evidence Probiotec and Pyridam relied on the following affidavits:(a)an affidavit of Benjamin James Friis-O’Toole (solicitor for Probiotec) dated 5 March 2024; (b)an affidavit of Jonathan Michael Wenig (chair and non-executive director of Probiotec) dated 21 March 2024; (c)an affidavit of Nadia Miranty Verdiana (Pyridam’s head of legal and company secretary) dated 21 March 2024;(d)a supplementary affidavit of Benjamin James Friis-O’Toole dated 25 March 2024; and(e)an affidavit of Jeremy Simon Lanzer (solicitor for Probiotec) dated 26 March 2024.The Scheme If the Scheme is implemented:(a)each person who owns PBP Shares (the Scheme Shareholders) on the “Scheme Record Date” (defined under the Scheme as 7:00pm on the fifth business day after the date on which the Scheme becomes effective or such other date agreed between Probiotec and Pyridam) will transfer their PBP Shares (the Scheme Shares) to Pyridam Australia; and(b)in consideration for that transfer, those shareholders will receive consideration of $3.00 per share (the Scheme Consideration). In its ASX announcement on 22 December 2023 in respect of the Scheme, Probiotec noted that the consideration of $3.00 per share constituted a 30% premium over the undisturbed share price of $2.31 (3 month volume weighted average price to 5 May 2023), a 26% premium over the 1 month volume weighted average price of $2.37 (to 21 December 2023) and a 19% premium over the share price of $2.52 on 21 December 2023, being the last trading day before the announcement. These figures are repeated in the draft scheme booklet. The draft scheme booklet also refers to the highest trading price in the three months before the announcement being $2.68 (13 October 2023) and the lowest being $2.18 (11 December 2023). The SID allows for certain dividends to be declared for the first half of financial year 2024 (1 July 2023 to 31 December 2023), and for the period between 1 January 2024 and the date that is immediately before the Scheme Record Date, without affecting the Scheme Consideration. Probiotec has declared the $0.035 per share dividend in respect of the first half of the 2024 financial year but has not, as yet, made any further declaration of dividends. The Scheme makes provision for the payment of funds by Pyridam Australia into a trust account in Probiotec’s name (Trust Account) before the Implementation Date (which is expected to be 18 June 2024). The transfer of the Scheme Shares to Pyridam Australia is subject to payment of the Scheme Consideration in the manner prescribed by the Scheme. Prior to the hearing, Pyridam and Pyridam Australia delivered an executed Deed Poll in favour of Scheme Shareholders. This executed Deed Poll is one of the annexures to the draft scheme booklet.

Decision

Reasons for decision

The exclusivity provisions are in a common form and contain the usual fiduciary carve-outs. They are not of concern. While break fees are also provided for, the amount of the fee is approximately 1% of the equity value of Probiotec as at the date of the SID. Moreover, the break fees are bilateral (ie also payable by the bidder). The break fees are also not a matter that ought to result in the Scheme not being put to a vote by Probiotec’s shareholders.CONCLUSION In this case, I am satisfied that, if the Scheme achieves the necessary majorities at the meeting, there is no reason that is presently apparent which would cause the court not to approve the Scheme at the second court hearing, if it is unopposed. Having regard to the matters set out above concerning the draft scheme booklet and the means by which it is to be distributed, I am also satisfied that Scheme Shareholders will be properly informed as to the nature of the Scheme before the meeting. Accordingly, orders were made on 26 March 2024 for the first meeting to be convened, together with ancillary orders.

Ratio Decidendi

Legal Principle Established

Mr Wenig also deposed, on information and belief, to the following facts in relation to Mr Gray:(a)as at 21 March 2024, he had a relevant interest in 60,000 PBP Shares; (b)he is a non-executive director of Probiotec and receives director’s fees from Probiotec; and(c)save for those matters he likewise has had no previous relationship or dealing with Probiotec or any person interested in the Scheme and has no interest or obligation that may give rise to a conflict of interest or duty if he were to act as chair of the meeting. CONSIDERATIONThe applicable principles As the procedural requirements have been satisfied, the court’s discretion to make the convening orders is enlivened. In its written submissions, Probiotec said as follows in relation to the applicable principles (footnotes omitted):16. The principles that apply upon an application to convene a scheme meeting are well-known and have been referred to in a number of recent decisions in this Court. The authorities make it clear that the Court’s function is supervisory and that it is not the Court’s role to usurp the shareholders’ decision by attempting to intrude its own commercial judgment. For example, in Re Amcor, Beach J described the Court’s role as follows:My function on an application to order the convening of a meeting is supervisory. At this stage I should generally confine myself to ensuring that certain procedural and substantive requirements have been met including dealing with adequate disclosure, with limited consideration of issues of fairness. But having said that, it is appropriate to consider the merits or fairness of a proposed scheme at the convening hearing if the issue is such as would unquestionably lead to a refusal to approve a proposed scheme at the approval hearing, that is, the proposed scheme appears now to be on its face “so blatantly unfair or otherwise inappropriate that it should be stopped in its tracks before going any further”. But in the present case, in my view there is no issue arising from the Scheme which would unquestionably lead to a refusal to approve the Scheme at the approval hearing. It cannot be said that the Scheme on its face is “so blatantly unfair or otherwise inappropriate that it should be stopped in its tracks before going any further”. Put another way, the Scheme is not of such a nature and cast in such terms that if it receives the support of the statutory majorities at the meeting, nevertheless I would not be likely to approve it at the second court hearing.17. It has consistently been held that the question whether or not to accept particular consideration for shares is quintessentially a commercial matter for the members to assess, and they ought not be prevented from having the opportunity to do so, provided that the Court can be satisfied that they are acting on sufficient information and with time to consider what they are voting on. Therefore, if the arrangement is one that seems fit for consideration by the meeting of members, and is a commercial proposition likely to gain the Court’s approval if passed by the necessary majorities, then orders should be made to convene and hold the meeting.